Search Results - "Tucker, Daniel M.D"

Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes: Results and projections from the Steno-2 study by Gæde, Peter, Valentine, William J, Palmer, Andrew J, Tucker, Daniel M.D, Lammert, Morten, Parving, Hans-Henrik, Pedersen, Oluf

“…OBJECTIVE:--To assess the cost-effectiveness of intensive versus conventional therapy for 8 years as applied in the Steno-2 study in patients with type 2…”
Get full text

The cost-effectiveness of interventions in diabetes: A review of published economic evaluations in the UK setting, with an eye on the future by Tucker, Daniel M.D, Palmer, Andrew J

“…Abstract Aim To synthesise key outcomes data from cost-effectiveness studies in diabetes, in the UK setting, and describe a narrative for the evidence-base, in…”
Get full text

Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes by Gæde, Peter, Valentine, William J., Palmer, Andrew J., Tucker, Daniel M.D., Lammert, Morten, Parving, Hans-Henrik, Pedersen, Oluf

“…Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes Results and projections from the Steno-2 study Peter Gæde…”
Get full text

196: Cost-Effectiveness of Aliskiren as Add on to Losartan and Optimal Antihypertensive Therapy in Patients with Type 2 Diabetes, Hypertension and Nephropathy in the UK Setting by Palmer, James L, Munk, Veronica C, Kotchie, Robert W, Vincze, Gabor, Charney, Alan, Tucker, Daniel M.D, Annemans, Lieven

Get full text

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes by Ray, Joshua A., Boye, Kristina S., Yurgin, Nicole, Valentine, William J., Roze, Stéphane, McKendrick, Jan, Tucker, Daniel M. D., Foos, Volker, Palmer, Andrew J.

“…ABSTRACT Objectives: The aim of this study was to evaluate the long-term clinical and economic outcomes associated with exenatide or insulin glargine, added to…”
Get full text

Counting the costs of overweight and obesity: modeling clinical and cost outcomes by Tucker, Daniel M. D., Palmer, Andrew J., Valentine, William J., Roze, Stéphane, Ray, Joshua A.

“…ABSTRACT Objective: To quantify changes in clinical and cost outcomes associated with increasing levels of body mass index (BMI) in a US setting. Research…”
Get full text

Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies by Palmer, Andrew J., Tucker, Daniel M. D., Valentine, William J., Roze, Stéphane, Gabriel, Sylvie, Cordonnier, Daniel J.

“…Background. To review published studies on the cost-effectiveness of the use of irbesartan for treatment of advance overt nephropathy in patients with type 2…”
Get full text

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension by Palmer, Andrew J., Valentine, William J., Tucker, Daniel M. D., Ray, Joshua A., Roze, Stéphane, Annemans, Lieven, Lapuerta, Pablo, Chen, Roland, Gabriel, Sylvie, Carita, Paulo, Rodby, Roger A., Zeeuw, Dick de, Parving, Hans-Henrik, Laville, Maurice

“…ABSTRACT Objectives: We performed a cost-consequence analysis in a French setting of the renoprotective benefit of irbesartan in hypertensive type 2 diabetes…”
Get full text